• We select business opportunities through the scientific team of the DREAVENT ecosystem. An experienced team with more than 20 exits with high multipliers.
• Companies from the World’s Best Life Sciences Hubs: Boston & USA, UK, Switzerland.
• Building truly differentiated science with global impact Significant unmet medical needs at an Agnostic Stage (preclinical - commercialization), with a clear and capital-efficient regulatory pathway. Strong and established IP position.
• Diversified pipeline with multiple “shots on goal” with hints of human efficacy or data in patients preferred; in large addressable Market.
• Exit Engineered: Relatively short timeline to value inflection. Indications and disease areas that have large-pharma partnership interest.


• We pick biotech companies with outstanding teams and experienced leadership with a track record of success.
• We choose the appropriate time of entry; minimizing the risk while maximizing with a high capital gain.
  • Nasdaq Pre-IPOs.
  • Preferred 2 years as maximum time frame for exit.
• We select transactions with high profitability.
• We select companies that already have relevant shareholders.